Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

University of Calgary

$15,000.00

Synthesis, resolution and applications of 3,3'-disubstituted BIPHEP and BINAP derivatives in asymmetric organic synthesis

EF 2007-08

Résumé
The goal of this proposal is to develop new asymmetric catalysts and reagents that will provide products of reactions with high enantioselectivity. Compounds that are marketed as drugs that contain one or more stereogenic centres can exist as two enantiomers. It is important that chemists design new asymmetric catalysts that allows for the production of one enantiomer selectively over the other as each enantiomer can behave differently within a chiral environment like the human body. Thus in order to market a new drug containing stereogenic centres, each anantiomer must be synthesized independent of the other and tested separately for unwanted side effects. This is not an easy task as enantiomers have the same chemical and physical properties in a non-chiral environment (i.e in the laboratory where they are synthesized). Thus chemists must design new asymmetric catalysts that allow for the formation of one enantiomer over the other in the laboratory. The design of catalysts outlined in this proposal should allow for the production of enantiomers selectively. By having to avoid a resolution, the cost of making the drug should be lower and thus ultimately the consumer should pay less for their prescriptions. Thus this research could ultimately benefit anyone needing drugs that contain stereogenic centres.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
335648-2005
Name nom
Keay, Brian
Department département
Chemistry
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2005
Award amount
15000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
2
Nb partie
2
Application title
Synthesis, resolution and applications of 3,3'-disubstituted BIPHEP and BINAP derivatives in asymmetric organic synthesis
Keyword
NA
Application summary
The goal of this proposal is to develop new asymmetric catalysts and reagents that will provide products of reactions with high enantioselectivity. Compounds that are marketed as drugs that contain one or more stereogenic centres can exist as two enantiomers. It is important that chemists design new asymmetric catalysts that allows for the production of one enantiomer selectively over the other as each enantiomer can behave differently within a chiral environment like the human body. Thus in order to market a new drug containing stereogenic centres, each anantiomer must be synthesized independent of the other and tested separately for unwanted side effects. This is not an easy task as enantiomers have the same chemical and physical properties in a non-chiral environment (i.e in the laboratory where they are synthesized). Thus chemists must design new asymmetric catalysts that allow for the formation of one enantiomer over the other in the laboratory. The design of catalysts outlined in this proposal should allow for the production of enantiomers selectively. By having to avoid a resolution, the cost of making the drug should be lower and thus ultimately the consumer should pay less for their prescriptions. Thus this research could ultimately benefit anyone needing drugs that contain stereogenic centres.